Skip to main content
Equibles
AVBP logo

AVBP · ArriVent BioPharma, Inc.

Track AVBP — free

Use AVBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AVBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.73 +0.02 (+0.12%) At close · Oct 9
Russell 2000 member Rebalance outlook locked
Market Cap
$824.92M
Shares
49.31M
Volume · Oct 9 1.73M Avg daily vol (3M) 921.51K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.73 Open$16.59 Day$16.49–17.76 52W close$15.09–34.74 Avg vol 30d1.5M Short int8.5M · 17.1% float · 11.3d Short vol73% Last earningsMay 11, 2026 DataJan 2024–Oct 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-20.8%
Trailing year
Short interest
17.1%
Latest settlement · 11.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg −42%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −42%
trailing
6-month return −47%
trailing
YTD return −17%
this year
Relative strength −57%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $29 › 200d $27 — 50d above 200d
Institutional flow Accumulating
4 of 159 funds reported for Sep 30 · net +268 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.14% of float · ▼ -3.6% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 2-yr high, broad support
Squeeze score 70
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −57%
past year
ATR 14.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
−42% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $29 › 200d $27 — 50d above 200d
Institutional flow Accumulating
4 of 159 funds reported for Sep 30 · net +268 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.14% of float · ▼ -3.6% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $17 · 8% Range high $35
vs 200-day avg -39% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AVBP
ArriVent BioPharma, Inc.
this stock
$824.92M -16.8% — — 17.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.83B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
159
% held
95.5%
Reported
4 of 159
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
151
View
Short & Settlement
Short Interest Falling
Shares short
8.5M
Days to cover
11.3d
Change
-314.8K sh
View
Short Volume
Short vol %
73%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$29
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
38.0%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-166.3M
EPS diluted
$-4.32
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 6, 2026
This year
11
View
Exempt Offerings
Offering
$145.0M
Filed
Dec 29, 2022
View
Earnings & Events
Webcasts
Last webcast
May 11, 2026
View

Performance

5D 20D 120D MTD YTD
AVBP -40.8% -42.3% -46.7% -44.8% -16.9%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -42.0% -44.2% -56.6% -46.8% -31.0%
Key facts CIK 1868279 CUSIP 04272N102 13F (30d) 6 filings 6 filers Visit website Investor relations